{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T01:13:09Z","timestamp":1794013989729,"version":"4.8.0"},"reference-count":62,"publisher":"Informa UK Limited","issue":"30","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,12,20]]},"DOI":"10.1080\/14796694.2025.2596228","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T10:21:21Z","timestamp":1765621281000},"page":"3891-3901","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score \u226550%: phase III study design"],"prefix":"10.1080","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-4462","authenticated-orcid":false,"given":"Martin","family":"Reck","sequence":"first","affiliation":[{"name":"Center for Lung Research, LungenClinic","place":["Grosshansdorf, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Lu","sequence":"additional","affiliation":[{"name":"Shanghai Jiao Tong University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth J.","family":"O\u2019Byrne","sequence":"additional","affiliation":[{"name":"Translational Research Institute and Queensland University of Technology","place":["Brisbane, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-5633","authenticated-orcid":false,"given":"Carlos","family":"Barrios","sequence":"additional","affiliation":[{"name":"Hospital S\u00e3o Lucas","place":["Porto Alegre, Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Pavlov","sequence":"additional","affiliation":[{"name":"Pfizer","place":["San Diego, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9685-1752","authenticated-orcid":false,"given":"Fabian","family":"Tay","sequence":"additional","affiliation":[{"name":"Pfizer","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8938-6699","authenticated-orcid":false,"given":"Marcelo V.","family":"Negrao","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"e_1_3_9_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834"},{"key":"e_1_3_9_4_1","unstructured":"Cancer.org. Atlanta (GA): American Cancer Society. Key Statistics for Lung Cancer; 2025 [cited 2025 Jul 22]. Available from: https:\/\/www.cancer.org\/cancer\/types\/lung-cancer\/about\/key-statistics.html"},{"key":"e_1_3_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2021.05.006"},{"key":"e_1_3_9_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00566-0"},{"key":"e_1_3_9_7_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2204.0023"},{"key":"e_1_3_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009"},{"key":"e_1_3_9_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.013"},{"key":"e_1_3_9_10_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0078"},{"key":"e_1_3_9_11_1","unstructured":"Keytruda (pembrolizumab) prescribing information. Rahway (NJ): Merck Sharp & Dohme; 2025 [cited 2025 Jul 22]. Available from: https:\/\/www.accessdata.fda.gov\/spl\/data\/211287cb-7401-4f31-b437-aafd5bf02a2f\/211287cb-7401-4f31-b437-aafd5bf02a2f.xml"},{"key":"e_1_3_9_12_1","unstructured":"European Medicines Agency. Keytruda (pembrolizumab) summary of product characteristics. [cited 2025 Jul 22]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf"},{"key":"e_1_3_9_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"e_1_3_9_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149"},{"key":"e_1_3_9_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00174"},{"key":"e_1_3_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7"},{"key":"e_1_3_9_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02885"},{"key":"e_1_3_9_18_1","unstructured":"FDA.gov. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS \u22651%). Silver Spring (MD): US Food and Drug Administration; 2019 [cited 2025 Aug 28]. Available from: https:\/\/www.fda.gov\/drugs\/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1"},{"issue":"2","key":"e_1_3_9_19_1","first-page":"117","article-title":"First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects","volume":"26","author":"Wang J","year":"2024","unstructured":"Wang J, Wu L. First-line immunotherapy for advanced non-small cell lung cancer: current progress and future prospects. Cancer Biol Med. 2024;26(2):117\u2013124.","journal-title":"Cancer Biol Med"},{"key":"e_1_3_9_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01989"},{"key":"e_1_3_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105073"},{"key":"e_1_3_9_22_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375136"},{"key":"e_1_3_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108458"},{"key":"e_1_3_9_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2007-8-5-215"},{"key":"e_1_3_9_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012346"},{"key":"e_1_3_9_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-22-0817"},{"key":"e_1_3_9_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-2307"},{"key":"e_1_3_9_28_1","doi-asserted-by":"publisher","DOI":"10.2174\/138945009788680374"},{"key":"e_1_3_9_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/19336918.2014.972788"},{"key":"e_1_3_9_30_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-0174"},{"key":"e_1_3_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.06.012"},{"issue":"2","key":"e_1_3_9_32_1","first-page":"659","article-title":"The cytoplasmic extension of the integrin \u03b26 subunit regulates epithelial-to-mesenchymal transition","volume":"34","author":"Lee C","year":"2014","unstructured":"Lee C, Lee C, Lee S, et al. The cytoplasmic extension of the integrin \u03b26 subunit regulates epithelial-to-mesenchymal transition. Anticancer Res. 2014;34(2):659\u2013664.","journal-title":"Anticancer Res"},{"key":"e_1_3_9_33_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M401736200"},{"key":"e_1_3_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2018.02.013"},{"key":"e_1_3_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1453"},{"key":"e_1_3_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.2543"},{"key":"e_1_3_9_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32137"},{"key":"e_1_3_9_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-0245"},{"key":"e_1_3_9_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu474"},{"key":"e_1_3_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2168"},{"key":"e_1_3_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2007.09.008"},{"key":"e_1_3_9_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-018-0249-7"},{"key":"e_1_3_9_43_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M312103200"},{"key":"e_1_3_9_44_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.bioconjchem.5c00202"},{"issue":"1","key":"e_1_3_9_45_1","first-page":"P1300","article-title":"First-in-human study of the theranostic pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in pancreatic adenocarcinoma","volume":"64","author":"Davis R","year":"2023","unstructured":"Davis R, Foster C, Ganguly T, et al. First-in-human study of the theranostic pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in pancreatic adenocarcinoma. J Nucl Med. 2023;64(Suppl 1):P1300.","journal-title":"J Nucl Med"},{"key":"e_1_3_9_46_1","unstructured":"ClinicalTrials.gov. A study of SGN-B6A versus docetaxel in previously treated non-small cell lung cancer. Bethesda (MD): National Library of Medicine; 2023 [cited 2025 Sep 9]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06012435"},{"key":"e_1_3_9_47_1","unstructured":"ClinicalTrials.gov. This is a study to learn about how the combination of the study medicines sigvotatug vedotin plus pembrolizumab works in people with non-small cell lung cancer with high levels of PD-L1. (Be6A Lung-02). Bethesda (MD): National Library of Medicine; 2025 [cited 2025 Sep 9]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT06758401"},{"key":"e_1_3_9_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8521"},{"key":"e_1_3_9_49_1","unstructured":"ClinicalTrials.gov. A study of Sigvotatug Vedotin in advanced solid tumors. Bethesda (MD): National Library of Medicine; 2020 [cited 2025 Sep 9]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04389632?cond=NSCLC&intr=sigvotatug%20vedotin&rank=3"},{"key":"e_1_3_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2021.115534"},{"key":"e_1_3_9_51_1","article-title":"A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001)","volume":"10","author":"Hollebecque A","year":"2022","unstructured":"Hollebecque A, Lopez JS, Piha-Paul SA, et al. A first-in-human trial of an integrin beta-6 targeted antibody-drug conjugate (ADC), SGN-B6A, in patients with advanced solid tumors: interim results of a phase 1 study (SGNB6A-001). J Immunother Cancer. 2022;10.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_9_52_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.3024"},{"key":"e_1_3_9_53_1","volume-title":"Oral presentation at: American Society for Clinical Oncology","author":"Sehgal K","year":"2024","unstructured":"Sehgal K, Corral Jaime J, Powell SF, et al. Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)\u2013directed antibody\u2012drug conjugate (ADC), and pembrolizumab combination therapy: initial results from an ongoing phase 1 study (SGNB6A-001). In: Oral presentation at: American Society for Clinical Oncology. Chicago, United States; 2024."},{"key":"e_1_3_9_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-2742"},{"key":"e_1_3_9_55_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0118"},{"key":"e_1_3_9_56_1","first-page":"A1","article-title":"SGN-B6A induces immunogenic cell death as a secondary mechanism of action","volume":"10","author":"Lyon RP","year":"2022","unstructured":"Lyon RP, Trang V, Gosink J, et al. SGN-B6A induces immunogenic cell death as a secondary mechanism of action. J Immunother Cancer. 2022;10:A1\u2013A1603.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_9_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-1522"},{"key":"e_1_3_9_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117"},{"key":"e_1_3_9_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00720"},{"key":"e_1_3_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.002"},{"key":"e_1_3_9_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_9_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8"},{"key":"e_1_3_9_63_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002879"},{"key":"e_1_3_9_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01990"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2596228","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14796694.2025.2596228","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2596228","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T19:19:45Z","timestamp":1782760785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2596228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":62,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2025,12,20]]}},"alternative-id":["10.1080\/14796694.2025.2596228"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2596228","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,13]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-11-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}